Combination therapy for melanoma: What are the current challenges in pricing & access from EU and US payers’ perspective?

By Tom Brockbank, Henrike Granzow and Alexandrosz Czira, GPI Current treatment options and target indications Malignant melanoma is the most lethal form of skin cancer1. In the UK approximately 15,400 new cases occur per year, and since the early 1990’s the incidence rate has more than doubled (128% increase)2. The incidence varies within Europe, from … More Combination therapy for melanoma: What are the current challenges in pricing & access from EU and US payers’ perspective?

Taking stock:  European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations  

Fertile ground for cross-border cooperation Even with pan-European EMA approval, pricing is still a country-level issue, with national governments, regional or local stakeholders and pharmaceutical companies being responsible for engaging in price formalities such as negotiations on a bilateral basis. But the landscape in Europe is beginning to show signs of change in how pricing … More Taking stock:  European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations  

Biosimilars in Oncology: Trastuzumab is taking off

Biosimilar launches of antineoplastic monoclonal antibodies represent a milestone in oncological care but also a new chapter in the application of biosimilars; introducing more prescribers, payers and stakeholders to the biological copies. Rituximab biosimilars came to the European market in 2017, while trastuzumab biosimilars have been keenly awaited since, and were first launched in the … More Biosimilars in Oncology: Trastuzumab is taking off

Pricing policy: Germany – a court ruling as soon as June could set a new tone for AMNOG pricing… but is access becoming a more complex moving target for industry?

Legal questions around the “Mischpreis” pricing approach are still hanging over sickness funds and manufacturers in Germany. The current price setting methodology as part of AMNOG negotiations take average weighted prices and considers the value and price potential across all indications and patient subgroups (‘mixed-price’). This methodology has been noted to be potentially at odds … More Pricing policy: Germany – a court ruling as soon as June could set a new tone for AMNOG pricing… but is access becoming a more complex moving target for industry?

Global Pricing Innovations (GPI) adds experienced, global Pharma Industry executive as Chief Operating Officer (COO) and senior pricing expert to lead pricing and consultancy.

Mark Morrison, who joins as COO, was previously with Novartis and had global and regional leadership roles based in Switzerland (Basel) and Indonesia (Jakarta). As a Global Brand Director Mark led global launches for Cardiovascular and Respiratory innovative pharmaceuticals. Within the Asia – Middle East – Africa region Mark was Franchise Head for the Primary … More Global Pricing Innovations (GPI) adds experienced, global Pharma Industry executive as Chief Operating Officer (COO) and senior pricing expert to lead pricing and consultancy.

What will shape the global pharmaceutical pricing environment in 2018?

One of the advantages of working in a global consultancy and technology solutions firm such as Global Pricing Innovations (GPI), which specializes in pharmaceutical pricing, is the wide exposure one receives to the many different challenges across disease areas, companies, and geographies. This forces us all at GPI to keep on our toes and gives … More What will shape the global pharmaceutical pricing environment in 2018?